TIDMMMC
RNS Number : 5317K
Management Consulting Group PLC
22 September 2016
22 September 2016
Management Consulting Group PLC
Interim Results
Management Consulting Group PLC ("MCG" or "the Group"), the
global professional services group, today announces its results for
the half-year ended 30 June 2016. These results reflect the Kurt
Salmon healthcare disposal completed on 29 July 2016 and the
proposed sale of Kurt Salmon Retail and Consumer Goods business
announced today, which are both reported as discontinued
operations.
Key points
-- Reported revenues from continuing operations (comprising
Alexander Proudfoot) down 12% year on year at GBP25.7m (H1 2015
restated: GBP29.3m)
-- Underlying* operating loss from continuing operations of
GBP1.9m (H1 2015 restated: loss of GBP0.4m)
-- Sale of the Kurt Salmon business in France and related
geographies completed in January 2016 for net proceeds of
approximately GBP57.7m used to repay indebtedness
-- Sale of the Kurt Salmon healthcare business completed on 29
July 2016 for net proceeds of approximately GBP7.7m
-- Proposed sale of the Kurt Salmon retail and consumer goods
business announced today for expected net proceeds of approximately
GBP121m- see separate announcement
-- Loss from discontinued operations of GBP16.8m (2015 H1 restated: GBP3.4m profit)
-- Retained loss for the half-year of GBP20.8m (H1 2015 restated: retained profit GBP1.4m)
-- Net cash balances** at 30 June 2016 of GBP1.9m (H1 2015: net debt of GBP41.7m)
* Throughout this statement the term 'underlying' is defined as
'before non-recurring items and amortisation of acquired intangible
assets'.
** Net cash/(debt) is cash and cash equivalents less financial
liabilities
Nick Stagg, Chief Executive, commented:
"This year has seen continuing restructuring of the Group and
the realisation of value for shareholders. Following completion of
the sale of Kurt Salmon's healthcare business in July, the Group
has today announced the proposed disposal of the Kurt Salmon retail
and consumer goods business to Accenture. The retained business of
the Group, Alexander Proudfoot, delivered higher revenues in the
first half of 2016 than in the second half of 2015, but has not yet
produced levels of revenue which restore the business to
profitability. The Board continues to focus on improving the
performance of Alexander Proudfoot."
For further information please contact:
Management Consulting Group PLC
Nick Stagg Chief Executive 020 7710 5000
Chris Povey Finance Director 020 7710 5000
FTI Consulting
Ben Atwell
Victoria Foster
Mitchell 0203 727 1000
Notes to Editors
Management Consulting Group PLC (MMC.L) provides professional
services across a wide range of industries and sectors. For further
information, visit www.mcgplc.com.
Chairman's Statement
Following completion of the sale of the French and related
operations of Kurt Salmon in January 2016, the Group completed the
previously announced sale of the US healthcare operations of Kurt
Salmon to ECG Management Consultants on 29 July, receiving gross
consideration on completion of $11.9m. Today the Group announced
the proposed sale of the retail, and consumer goods business of
Kurt Salmon to Accenture for an expected total gross consideration
of approximately $165m. Further details of the proposed disposal,
which is conditional, inter alia, upon the approval of MCG
shareholders are contained in the announcement made today and will
be set out in a Circular sent to shareholders in due course.
The results of the Kurt Salmon healthcare and the Kurt Salmon
retail and consumer goods businesses for the first six months of
2016, and some final elements of the French disposal, are reported
in the interim results as discontinued operations. Discontinued
operations also include the impact of the impairment of goodwill
attributed to the Kurt Salmon healthcare business. The financial
impact of the proposed disposal of the Kurt Salmon retail and
consumer goods business, including the expected profit on sale,
will be reported in the second half of 2016, assuming that the
transaction proceeds to completion as expected.
The continuing operations of the Group for the first six months
of 2016 comprise Alexander Proudfoot. After a poor performance in
the second half of 2015, we saw some positive momentum in Alexander
Proudfoot in the first half of 2016, with revenues growing over the
first two quarters, although we have not yet generated levels of
revenue that restore the business to profitability.
The disposal of the French and related operations of Kurt Salmon
in January allowed the Group to repay its bank borrowings in full.
The Group was in a strong financial position at 30 June 2016, with
net cash, before the further positive impact of the proceeds from
the Kurt Salmon healthcare disposal. The expected net cash proceeds
from the proposed sale of the Kurt Salmon retail and consumer goods
business will allow the Group to consider returning value to
shareholders.
Looking forward, the Board continues to focus on the need to
improve the performance of Alexander Proudfoot.
Alan Barber
Chairman
Operating and financial review
Continuing and discontinued operations
References below to continuing operations relate to Alexander
Proudfoot.
The French and related operations of Kurt Salmon were reported
as discontinued operations in the Group financial statements for
the year ended 31 December 2015 and the financial impact of the
finalisation of the disposal of those businesses (which completed
on 7 January 2016) is reported in the discontinued operations
section of the Group income statement for the six month period
ended 30 June 2016.
The sale of the Kurt Salmon healthcare business was completed on
29 July 2016, however given that the Board of MCG had committed to
the disposal and negotiations for the sale of the business were at
an advanced stage at 30 June 2016, the results of its operations
and the loss on disposal arising from the impairment of goodwill
are reported as discontinued operations in the Group income
statement for the six month period ended 30 June 2016. The
comparatives for the six month period ended 30 June 2015 have been
restated on the same basis in relation to continuing and
discontinued operations. The assets and liabilities of the Kurt
Salmon healthcare business are reflected in the Group balance sheet
at 30 June 2016 as assets and liabilities held for sale, being
GBP9.3m and GBP1.5m respectively. The assets held for sale include
the impaired goodwill related to the Kurt Salmon healthcare
business of GBP5.8m.
The proposed sale of the Kurt Salmon retail and consumer goods
consulting practice was announced today. Given that the Board of
MCG had committed to the disposal and negotiations for the sale of
the business were underway at 30 June 2016, the results of its
operations are reported as discontinued operations in the Group
income statement for the six month period ended 30 June 2016. The
comparatives for the six month period ended 30 June 2015 have been
restated on the same basis in relation to continuing and
discontinued operations. The assets and liabilities of the Kurt
Salmon retail and consumer goods business are reflected in the
Group balance sheet at 30 June 2016 as assets and liabilities held
for sale, being GBP132.4m and GBP41.4m respectively. The assets
held for sale include the goodwill related to the Kurt Salmon
retail and consumer goods business of GBP94.3m. The sale of the
Kurt Salmon retail and consumer goods consulting practice is
expected to give rise to a profit on disposal which will be
accounted for when the transaction completes, which is expected to
be in the second half of 2016.
Alexander Proudfoot
The continuing operations of the Group comprise Alexander
Proudfoot. Following a poor performance in the second half of 2015,
in the first half of 2016 Alexander Proudfoot delivered two
quarters of solid revenue growth, although not achieving the levels
recorded in the first half of 2015. Alexander Proudfoot's reported
revenue for the first half of 2016 was GBP25.7m, 23% higher than
the preceding six month period (H2 2015: GBP20.8m), and 12% lower
than the same period in 2015 (H1 2015: GBP29.3m). At H1 2015
exchange rates, H1 2016 revenues would have been higher at
GBP26.3m, the reported revenue reflecting the negative impact in
the first half of 2016 of weakening of the Brazilian Real and the
South African Rand offset to some extent by the stronger US dollar.
The business reported a GBP1.9m underlying operating loss in the
first half of 2016 compared with a GBP0.4m operating loss for the
first half of 2015 and a GBP5.3m loss for 2015 as a whole.
Work for clients in the natural resources sector continued to
represent a significant proportion of Alexander Proudfoot's
activities, being 46% of total revenues in the first half of 2016
(H1 2015: 50%). In spite of continuing overall weakness in this
sector, which has had a significant adverse impact on Alexander
Proudfoot's revenues in the last two years, the business has been
successful this year in securing an increased level of work from
larger global mining groups rather than the mid-market players who
have been most affected by sector weakness.
The strong first half performance of the North American business
seen in 2015 was not repeated in the first half of 2016, with
revenues down more than one third on the same period in 2015. This
disappointing result was countered to some extent by a much
improved performance in Brazil and elsewhere in South America. The
European business delivered a slightly improved performance
compared with the previous six months, although revenue levels were
still below those of the same period in 2015. In the smaller
operations in Africa and Asia there was some progress in the first
half, but revenues levels here remain too low.
Summary and outlook
The year to date has seen the continued restructuring of the
Group and the realisation of value for shareholders.
Alexander Proudfoot reported lower revenues year on year and an
underlying operating loss in the first half of 2016. Order input in
the early part of 2016 was encouraging but from the second quarter
activity levels slowed and the current order book is weaker than it
was at the beginning of 2016. As a result, the Board expects that
revenues in the third quarter of 2016 will be lower than those in
the second quarter. Accordingly, the outcome for the year as a
whole for Alexander Proudfoot remains uncertain and will depend on
order input in the coming months.
Following completion of the proposed Disposal, the trading
operations of the Group will solely comprise Alexander Proudfoot.
Alexander Proudfoot has experienced a difficult trading environment
in the past two years but it is a long established business which
has been successful over many decades and continues to deliver
successful outcomes for its clients. The Board of MCG remains
committed to improving the performance of Alexander Proudfoot and
restoring the business to profitable growth.
Certain existing back-office operations of Kurt Salmon in the
United States will not form part of the business being sold to
Accenture. As a result, certain office leases, supplier and other
contracts and personnel currently supporting Kurt Salmon will be
retained by MCG following completion and will be used to support
transitional services agreements with Accenture and the existing
transitional service agreements with Solucom and ECG Management
Consultants, the acquirers of the French and related operations and
the healthcare operations of Kurt Salmon respectively. Following
the proposed disposal, and as the transitional services
arrangements with these acquirers fall away over time, the Group
will need to make changes to the existing back office functions to
reduce costs, in the United States in particular. The Group is also
likely to seek to make other changes to its cost base to reflect
the reduced scale of the continuing operations of the Group.
The disposal of the French and related operations of Kurt Salmon
in January 2016 allowed the Group to repay its indebtedness in
full. MCG is in a strong financial condition with net cash at 30
June 2016 of GBP1.9m (2015 H1: net debt GBP41.7m) and a GBP12.5m
working capital banking facility in place. The net proceeds from
the subsequent sale of the Kurt Salmon healthcare business further
strengthened the balance sheet and the expected proceeds from the
proposed sale of the Kurt Salmon retail and consumer goods business
will enable the Group to consider returning value to
shareholders.
The Board will continue to monitor the implications for the
Group of the current uncertainty following the UK EU referendum
result. Approximately 97 % of MCG's revenue from continuing
operations in the first half of 2016 was derived from, and is
broadly generated, by consulting staff and operations based outside
the UK and approximately 55% of Group revenue from continuing
operations in the first half of 2016 was billed in US Dollars. The
significant weakening of Sterling against the US Dollar in the wake
of the referendum vote, will, if it persists, have a positive
effect on the reported revenues of the Group in the near term,
although further weakness in emerging market currencies will have a
countervailing effect.
Group Financial Summary
Exchange rates
In the first half of 2016 approximately 3% of the Group's total
revenues from continuing operations were billed in Sterling (H1
2015 restated: 3%), with approximately 55% of the Group's revenues
from continuing operations denominated in US Dollars and nearly 15%
in Euros. The average exchange rates to Sterling used in the first
half of 2016 were GBP1 = $1.43 (H1 2015: GBP1 = $1.53) and GBP1 =
EUR1.28 (H1 2015: GBP1 = EUR1.37). Comparing the first half periods
in 2015 and 2016, Sterling therefore weakened by more than 7%
against both the US Dollar and the Euro.
The closing exchange rates to Sterling used in balance sheet
translation at 30 June 2016 were GBP1 = $1.33 (H1 2015: GBP1 =
$1.57) and GBP1 = EUR1.20 (H1 2015: GBP1 = EUR1.41).
Revenue from continuing operations
Reported revenue from continuing operations, comprising revenues
from Alexander Proudfoot, was GBP25.7m for the first half of 2016,
12% lower than the same period in the previous year (H1 2015:
GBP29.3m).
Revenue from continuing operations from the Americas decreased
by GBP2.6m to GBP17.2m (H1 2015 restated: GBP19.8m). Revenue from
Europe in the first half was GBP0.9m lower than the corresponding
period in 2015 at GBP5.9m (H1 2015 restated: GBP6.8m) and Rest of
World revenue was steady at GBP2.8m (H1 2015 restated: GBP2.8m).
This analysis reflects the geographies in which the business units
generating the revenues are located and does not wholly reflect the
locations in which work is delivered.
Underlying operating loss from continuing operations
The underlying operating loss from continuing operations for the
period was GBP1.9m, some GBP1.5m higher than the corresponding
period in 2015 (2015 H1 restated: GBP0.4m).
Non-recurring items relating to continuing operations for the
first half of 2016 were a net credit of GBP0.6m relating to a
provision release in respect of the deregistration of the Alexander
Proudfoot Australian company and a gain on the disposal of a Swiss
holding company prior to the disposal of the French and related
operations of Kurt Salmon (H1 2015 restated: GBP0.4m expense).
Amortisation of acquired intangibles was GBP0.3m (H1 2015 restated:
GBP0.3m).
The operating loss from continuing operations for the first half
of 2016 was GBP1.6m (H1 2015 restated: GBP0.2m).
Interest
The total net finance costs for the period were GBP0.6m (H1 2015
restated: GBP0.9m).
Taxation
Loss before tax from continuing operations for the first half of
2016 was GBP2.2m (H1 2015 restated: GBP1.1m). Underlying loss
before tax for the period was GBP2.5m (H1 2015 restated: GBP1.2m).
The tax rate on the underlying loss before tax was 82% (H1 2015
restated: 83%). The continuing high underlying tax rate in the
period reflects the impact of revenue based taxes and
project-specific withholding taxes in Alexander Proudfoot.
Discontinued operations
Discontinued operations in the six months ended 30 June 2016
relate to Kurt Salmon.
The sale of Kurt Salmon's healthcare business was completed on
29 July 2016. Revenues from the Kurt Salmon healthcare discontinued
operations were GBP7.3m (2015 H1 restated: GBP8.6m). The underlying
operating loss from the Kurt Salmon healthcare discontinued
operations was GBP1.0m (2015 H1 restated: underlying operating
profit GBP0.1m). This loss reflects a weaker revenue performance in
the first six months of 2016 and the write-off of a receivable
relating to certain non-US healthcare operations which are being
discontinued as a result of the disposal of the business.
Non-recurring expenses relating to the Kurt Salmon healthcare
discontinued operations were GBP1.6m, comprising GBP0.6m related to
the restructuring of certain healthcare consulting operations which
did not form part of the business being sold and expenses related
to share awards of GBP1.0m.
The loss on disposal of GBP16.4m for the Kurt Salmon healthcare
business, reported as part of the loss from discontinued operations
in the Group income statement for the six months ended 30 June
2016, arises as a result of the impairment of goodwill relating to
the business which has been sold. The gross cash proceeds paid by
the acquirer at completion were $11.9m (equivalent to GBP9.0m) and
the net proceeds after transaction costs were GBP7.7m. The
consideration is subject to post-closing adjustments relating to
working capital and other balance sheet items and the reported loss
on disposal reflects estimates of the impact of such
adjustments.
The completion of the disposal of the Kurt Salmon healthcare
business in July 2016 is expected to give rise to a taxable gain in
the US, the tax charge on which is estimated at approximately
GBP1.8m. This will be reflected in the full year Group income
statement for 2016 and is not reported in the loss on sale for the
six months ended 30 June 2016.
The proposed sale of Kurt Salmon's retail and consumer goods
business was announced today. Revenues from the Kurt Salmon retail
and consumer goods discontinued operations were GBP40.4m, which is
GBP3.3m or 9% higher than the corresponding first half revenue in
2015 of GBP37.1m. On a constant currency basis Kurt Salmon's H1
2016 revenues would have been GBP37.9m, an increase of 2% on the
same period, reflecting the positive impact of the stronger US
dollar on reported 2016 revenues.
Underlying operating profit from the Kurt Salmon retail and
consumer goods discontinued operations was GBP3.9m (H1 2015
restated: GBP3.7m), representing a margin of approximately 10% and
consistent with the margin reported in the first half of 2015.
Kurt Salmon's operations in North America represented
approximately 70% of the Kurt Salmon retail and consumer goods
business as a whole in terms of reported revenue in the first half
of 2016. The US retail and consumer goods practice delivered a good
performance in the first half of 2016, with revenues approximately
6% ahead of the same period in 2015 on a constant currency basis,
and at an improved margin. The acquisition of Mobispoke in the
second half of 2015 has allowed Kurt Salmon to promote a focused
digital offering for clients this year, branded as KS Digital.
Approximately 20% of Kurt Salmon's revenues were generated in
Europe, led by operations in Germany and the UK. Both practices
were successful in the first half of 2016 with Germany performing
well, although not quite at the high revenue levels achieved in the
first half of 2015, and the UK business delivering a strong
performance. Kurt Salmon's operations in Asia were a relatively
small proportion of the business as a whole, representing
approximately 10% of revenues.
Non-recurring expenses relating to the Kurt Salmon retail and
consumer goods discontinued operations were GBP0.7m, largely
relating to part of the consideration payable for the acquisition
of Mobispoke by Kurt Salmon (completed in 2015) which is required,
under IFRS3, to be treated as remuneration in the Group income
statement. The tax charge relating to the Kurt Salmon retail and
consumer goods discontinued operations was GBP1.6m (2015 H1
restated GBP2.3m). Consequently the profit after taxation on the
Kurt Salmon retail and consumer goods discontinued operations was
GBP1.5m (2015 H1 restated: GBP1.3m).
As expected, discontinued operations in the six months ended 30
June 2016 also reflect the impact of the finalisation of the
disposal of the French and related operations of Kurt Salmon sold
in January 2016, primarily comprising the recycling of a GBP3.2m
currency translation reserve to the profit and loss account and a
tax charge of GBP1.5m relating to the disposal.
Earnings per share
The basic loss per share for continuing operations was 0.8p (H1
2015 restated: 0.4p per share) and the underlying basic loss per
share was 0.9p (H1 2015 restated: 0.5p per share).
Balance Sheet
The assets and liabilities of the French and related operations
of Kurt Salmon were shown in the Group balance sheet at 31 December
2015 as assets and liabilities held for sale of GBP91.8m and
GBP33.1m respectively.
The Group balance sheet at 30 June 2016 reflects the impact of
the disposal in July 2016 of the healthcare operations of Kurt
Salmon and the proposed disposal of the retail and consumer goods
operations of Kurt Salmon which was announced today.
The assets and liabilities of the Kurt Salmon healthcare
business are shown in the Group balance sheet as assets and
liabilities held for sale of GBP9.3m and GBP1.5m respectively. The
assets held for sale include the impaired goodwill and other
intangible assets related to the business which has been sold of
GBP5.8m.
The assets and liabilities of the Kurt Salmon retail and
consumer goods business are shown in the Group balance sheet as
assets and liabilities held for sale of GBP132.4m and GBP41.4m
respectively. The assets held for sale include the goodwill and
other intangible assets related to the business which will be sold
of GBP94.3m.
The net assets of the Group have decreased from GBP129.3m at 31
December 2015 to GBP114.8m at 30 June 2016, primarily as a result
of the loss on the disposal of the Kurt Salmon healthcare
business.
The proceeds from the sale of the French and related operations
of Kurt Salmon allowed the Group to repay its indebtedness in full
and there was a net cash position of GBP1.9m at 30 June 2016.
The Group was financed by a GBP15m working capital facility in
the first half of 2016 which was reduced to a GBP12.5m facility
following the sale of the Kurt Salmon Healthcare business in July.
At 30 June 2016 the gross debt drawn under this facility reflected
in the Group balance sheet was GBP6.1m held in Euros and US
Dollars.
The net post-retirement obligations liability relates to a
closed US defined benefit pension scheme and a post-retirement
medical benefits plan, both in Alexander Proudfoot, and has
decreased from GBP21.8m at 31 December 2015 to GBP17.7m at 30 June
2016.
The Board's assessment in relation to going concern is included
in Note 2 of the financial information. Principal risks and
uncertainties are set out in Note 2 of the financial
information.
There have been no transactions with or material changes to
related parties that have materially affected
the financial position or performance of the Group during the
period.
Directors' responsibility statement
The directors are responsible for the maintenance and integrity
of corporate and financial information. Legislation in the United
Kingdom governing the preparation and dissemination of financial
statements may differ from legislation in other jurisdictions.
We confirm that, to the best of our knowledge:
(a) the condensed set of financial statements has been prepared
in accordance with IAS 34 Interim Financial Reporting;
(b) the Operating and Financial Review includes a fair review of
the information required by DTR 4.2.7R (indication of important
events during the first six months and description of principal
risks and uncertainties for the remaining six months of the year);
and
(c) the Operating and Financial Review includes a fair review of
the information required by DTR 4.2.8R (disclosure of related
parties' transactions and changes therein).
By order of the Board
Chris Povey
Finance Director
September 2016
Cautionary statement
The Chairman's Statement and the Operating and Financial Review
have been prepared solely to provide additional information to
shareholders to assess the Group's strategies and the potential for
those strategies to succeed. They should not be relied on by any
other party or for any other purpose.
They contain certain forward-looking statements. These
statements are made by the directors in good faith based on the
information available to them up to the time of their approval of
this report but such statements should be treated with caution due
to the inherent uncertainties, including both economic and business
risk factors, underlying any such forward-looking information.
Condensed Group statement of profit and loss
for the six months ended 30 June 2016
Unaudited Unaudited
six months six months
ended ended
30 June
30 June 2015
2016 restated
Note GBP'000 GBP'000
--------------------------------------------- ---- ---------- ------------
Continuing operations
Revenue 3 25,694 29,322
Cost of sales (12,928) (14,061)
--------------------------------------------- ---- ---------- ------------
Gross profit 12,766 15,261
--------------------------------------------- ---- ---------- ------------
Administrative expenses - underlying (14,693) (15,631)
Loss from operations - underlying (1,927) (370)
Administrative expenses - non-recurring 654 435
--------------------------------------------- ---- ---------- ------------
(Loss)/ profit from operations
before amortisation of acquired
intangibles (1,273) 65
Administrative expenses - amortisation
of acquired intangibles (304) (303)
--------------------------------------------- ---- ---------- ------------
Total administrative expenses (14,343) (15,499)
--------------------------------------------- ---- ---------- ------------
Loss from operations 3 (1,577) (238)
Investment income 22 1
Finance costs (603) (872)
--------------------------------------------- ---- ---------- ------------
Loss before tax (2,158) (1,109)
Tax 5 (1,773) (925)
--------------------------------------------- ---- ---------- ------------
Loss for the period from continuing
operations (3,931) (2,034)
(Loss)/profit from discontinued
operations 8 (16,832) 3,441
--------------------------------------------- ---- ---------- ------------
(Loss)/profit for the period (20,763) 1,407
--------------------------------------------- ---- ---------- ------------
(Loss)/Earnings per share -
pence
From loss from continuing operations
for the period
Basic 6 (0.8) (0.4)
Diluted 6 (0.8) (0.4)
Basic - underlying 6 (0.9) (0.5)
Diluted - underlying 6 (0.9) (0.5)
From the (loss)/profit for the
period
Basic 6 (4.2) 0.3
Diluted 6 (4.2) 0.3
Basic - underlying 6 (4.0) 0.2
Diluted - underlying 6 (4.0) 0.2
-------------------------------------------- ---- ---------- ----------
Condensed Group statement of comprehensive income
for the six months ended 30 June 2016
Unaudited Unaudited
six months six months
ended ended
30 June
2016 30 June 2015
GBP'000 GBP'000
-------------------------------------------- ---------- ------------
(Loss)/profit for the period (20,763) 1,407
Items that will not subsequently be
reclassified to profit and loss
Remeasurement of defined benefit pension
schemes (4,604) 1,507
Items that may subsequently be reclassified
to profit and loss
Gain on available-for-sale investments 6 -
Exchange differences on translation
of foreign operations 9,945 (10,797)
-------------------------------------------- ---------- ------------
9,951 (10,797)
-------------------------------------------- ---------- ------------
Total comprehensive expense for the
period attributable to owners of the
Company (15,416) (7,883)
-------------------------------------------- ---------- ------------
Condensed Group statement of changes in equity
for the six months ended 30 June 2016
Shares
held
by
Share employee
Share Share Merger compensation benefit Translation Other Retained
capital premium reserve reserve trust reserve reserves earnings Total
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
-------------- --------- --------- --------- ------------ -------- ------------ --------- --------- ---------
Balance as
at
1 January
2015 84,518 82,362 32,513 5,737 (3,063) 19,029 6,082 (29,513) 197,665
-------------- --------- --------- --------- ------------ -------- ------------ --------- --------- ---------
Total
comprehensive
expense for
the period - - - - - (10,797) - 2,914 (7,883)
Share-based
payments - - - 1,240 - - - - 1,240
Vesting of
share awards - - - (961) - - - 81 (880)
Shares
transferred
by ESOP - - - - 787 - - - 787
Dividends
paid - - - - - - - (4,018) (4,018)
-------------- --------- --------- --------- ------------ -------- ------------ --------- --------- ---------
Unaudited
balance at
30 June 2015 84,518 82,362 32,513 6,016 (2,276) 8,232 6,082 (30,536) 186,911
-------------- --------- --------- --------- ------------ -------- ------------ --------- --------- ---------
Total
comprehensive
expense for
the period - - - - - 9,059 - (67,517) (58,458)
Shares issued 20 302 - - - - - - 322
Share-based
payments - - - 557 - - - - 557
Vesting of
share awards - - - (2,394) - - - 1,947 (447)
Shares
transferred
from ESOP - - - - 421 - - - 421
Recycling
of merger
reserve - - (26,830) - - - - 26,830 -
-------------- --------- --------- --------- ------------ -------- ------------ --------- --------- ---------
Audited
balance
at
31 December
2015 84,538 82,664 5,683 4,179 (1,855) 17,291 6,082 (69,276) 129,306
-------------- --------- --------- --------- ------------ -------- ------------ --------- --------- ---------
Total
comprehensive
expense for
the period - - - - - 9,945 6 (25,367) (15,416)
Shares issued 81 - - - - - - - 81
Share-based
payments - - - 1,329 - - - - 1,329
Vesting of
share awards - - - (3,032) - - - 2,556 (476)
Shares
transferred
from ESOP - - - - 7 - - - 7
-------------- --------- --------- --------- ------------ -------- ------------ --------- --------- ---------
Unaudited
balance at
30 June 2016 84,619 82,664 5,683 2,476 (1,848) 27,236 6,088 (92,087) 114,831
-------------- --------- --------- --------- ------------ -------- ------------ --------- --------- ---------
Condensed Group statement of financial position
as at 30 June 2016
Unaudited Audited
30 June 31 Dec
2016 2015
GBP'000 GBP'000
--------------------------------- --------- ---------
Non-current assets
Intangible assets & goodwill 46,999 148,387
Property, plant and equipment 575 1,996
Investments 275 711
Deferred tax assets 5,659 14,448
--------------------------------- --------- ---------
Total non-current assets 53,508 165,542
--------------------------------- --------- ---------
Current assets
Trade and other receivables 8,462 29,115
Current tax receivables 205 1,096
Cash and cash equivalents 7,983 15,478
Assets held for sale 141,689 91,785
--------------------------------- --------- ---------
Total current assets 158,339 137,474
--------------------------------- --------- ---------
Total assets 211,847 303,016
--------------------------------- --------- ---------
Current liabilities
Financial Liabilities - (68,294)
Trade and other payables (25,263) (39,875)
Current tax liabilities (3,650) (4,020)
Liabilities held for sale (42,919) (33,105)
--------------------------------- --------- ---------
Total current liabilities (71,832) (145,294)
--------------------------------- --------- ---------
Net current assets/(liabilities) 86,507 (7,820)
--------------------------------- --------- ---------
Non-current liabilities
Financial liabilities (6,063) -
Retirement benefit obligations (17,658) (21,781)
Deferred tax liabilities (814) (5,413)
Long-term provisions (649) (1,222)
--------------------------------- --------- ---------
Total non-current liabilities (25,184) (28,416)
--------------------------------- --------- ---------
Total liabilities (97,016) (173,710)
--------------------------------- --------- ---------
Net assets 114,831 129,306
--------------------------------- --------- ---------
Equity
Share capital 84,619 84,538
Share premium account 82,664 82,664
Merger reserve 5,683 5,683
Share compensation reserve 2,476 4,179
Shares held by employee benefit
trust (1,848) (1,855)
Translation reserve 27,236 17,291
Other reserves 6,088 6,082
Retained earnings (92,087) (69,276)
--------------------------------- --------- ---------
Equity attributable to owners of
the Company 114,831 129,306
--------------------------------- --------- ---------
Condensed Group statement of cash flows
for the six months ended 30 June 2016
Unaudited Unaudited
six months six months
ended ended
30 June 30 June
2016 2015
Note GBP'000 GBP'000
---------------------------------------- ---- ---------- ----------
Net cash outflow from operating
activities 7 (5,688) (7,070)
---------------------------------------- ---- ---------- ----------
Investing activities
Interest received 22 9
Purchases of property, plant
and equipment (257) (318)
Purchases of intangible assets (117) (126)
Proceeds on disposal of financial
instruments - 92
Proceeds from disposals of subsidiaries 54,363 -
---------------------------------------- ---- ---------- ----------
Net cash generated from/(used
in) continuing investing activities 54,011 (343)
---------------------------------------- ---- ---------- ----------
Financing activities
Dividends paid (3) (1,116)
Interest paid (241) (992)
Proceeds from borrowings 5,633 12,481
Repayment of borrowings (68,294) (13,988)
Net cash outflow from continuing
financing activities (62,905) (3,615)
---------------------------------------- ---- ---------- ----------
Net decrease in cash and cash
equivalents (14,582) (11,028)
Cash and cash equivalents at
beginning of period 20,737 24,920
Effect of foreign exchange rate
changes 1,828 (1,968)
---------------------------------------- ---- ---------- ----------
Cash and cash equivalents at
end of period 7,983 11,924
---------------------------------------- ---- ---------- ----------
Notes
1. General information
The results for the six months ended 30 June 2016 and 30 June
2015 are unaudited but have been reviewed by the Group's auditor,
whose report on the current period forms part of this document. The
information for the year ended 31 December 2015 does not constitute
statutory accounts as defined in Section 434 of the Companies Act
2006. A copy of the statutory accounts for that year has been
delivered to the Registrar of Companies. The auditor's report on
those accounts was not qualified or modified, did not include a
reference to any matters to which the auditor drew attention by way
of emphasis without qualifying the report and did not contain
statements under Section 498 (2) or (3) of the Companies Act
2006.
2. Significant accounting policies
(a) Basis of preparation
The annual financial statements of the Group are prepared in
accordance with International Financial Reporting Standards as
adopted by the European Union and are available on our website:
www.mcgplc.com. The set of condensed financial statements included
in this half-yearly report has been prepared in accordance with
International Accounting Standard 34 Interim Financial Reporting,
as adopted by the European Union.
(b) Accounting policies
In the current financial year the Group has adopted the
following newly effective standards and amendments, none of which
have had a material impact:
Annual improvements 2010-2012 Cycle
Annual improvements 2012-2014 Cycle
Amendments to IFRS11: Accounting for Acquisitions of Interests
in Joint Operations
Amendments to IAS6 and IAS38: Classification of acceptable
methods of depreciation and amortisation
Amendments to IAS27: Equity method in separate financial
statements
Amendments to IAS1: Disclosure initiative
Principal risks and uncertainties
The Group has operating and financial policies and procedures
designed to maximise shareholder value within a defined risk
management framework.
The key risks to which the business is exposed are reviewed
regularly by senior management and the Board as a whole.
The major risks the business faces are consistent with those set
out in the Company's Annual Report for the year ended 31 December
2015. They are related to the demand for consultancy services in
each of the markets and sectors in which the Group operates;
retention and development of key client relationships, recruitment
and retention of talented employees; optimisation of the Group's
intellectual capital; and fluctuations in foreign exchange currency
rates.
These risks are managed by anticipating consultancy trends;
identifying new markets and sectors in which the Group might
operate; maximising staff utilisation; having remuneration policies
which reward performance and promote continued employment with the
Group; maintaining a comprehensive knowledge management system; and
undertake hedging to mitigate currency risk where appropriate.
Potential contractual liabilities arising from client
engagements are managed through careful control of contractual
conditions and appropriate insurance arrangements. There is no
material outstanding litigation against the Group of which the
Directors are aware which is not covered by insurance, or provided
for in the financial statements.
Going concern
The Group's business activities, together with the factors
likely to affect its future development, performance and position,
and the financial position of the Group, its cash flows, liquidity
position and borrowing facilities are set out in the Chairman's
statement. Principal risks and uncertainties are described
above.
The Group prepares regular business forecasts and monitors its
projected compliance with its banking covenants, which are reviewed
by the Board. Forecasts are then adjusted for sensitivities which
address the principal risks to which the Group is exposed.
Consideration is then given to the potential actions available to
management to mitigate the impact of one or more of these
sensitivities if required.
The Board has concluded that the Group should be able to operate
within the level of its current facility and remain covenant
compliant for the foreseeable future, being a period of at least
twelve months from the date of approval of this half-yearly
report.
Accordingly, they continue to adopt the going concern basis in
preparing the annual report and financial statements.
Discontinued operations and assets held for sale
The Disposal of Kurt Salmon healthcare practice and the
recognition of assets held for sale at the lower of cost and fair
value less costs to sell required judgement to be applied to both
post-completion consideration and goodwill allocated to the
disposal group. The loss on disposal reflects a best estimate of
final proceeds based on the information available at the signing
date of the accounts.
The assets and liabilities held for sale in respect of the Kurt
Salmon retail and consumer goods consulting business are recognised
at the lower of cost and fair value less costs to sell.
With regard to the allocation of goodwill, the two disposal
groups identified on 30 June 2016 required Kurt Salmon goodwill to
be allocated between the disposal groups. As there is no prescribed
allocation measures under IFRS, 2015 revenues have been used as an
appropriate measure of relative value. Further details of the
goodwill allocated to the disposal group are set out in note 8
3. Segmental information
The continuing operations of the Group comprise Alexander
Proudfoot. This is the basis on which information is provided to
the Board of Directors for the purposes of allocating certain
resources within the Group and assessing the performance of the
business. The segments for this purpose are the Americas, Europe
and the Rest of World. All revenues are derived from the provision
of professional services.
Inter-segmental sales are not significant.
Income statement
Revenue and underlying operating profit by geography
The Group operates in three geographical areas; the Americas,
Europe and the Rest of World. The following is an analysis of
financial information by geographic segment:
Unaudited six months
ended 30 June 2016
-----------------------------------------------
Rest
of
Americas Europe World Consolidated
GBP'000 GBP'000 GBP'000 GBP'000
------------------------------------- ---------- --------- -------- --------------
Revenue - continuing operations 17,226 5,896 2,572 25,694
------------------------------------- ---------- --------- -------- --------------
Profit/(loss) from operations
- underlying 525 (1,460) (992) (1,927)
------------------------------------- ---------- --------- -------- --------------
Non-recurring items and amortisation
of acquired intangibles (199) 296 253 350
Profit/(loss) from operations 326 (1,164) (739) (1,577)
------------------------------------- ---------- --------- -------- --------------
Investment income 22
Finance costs (603)
------------------------------------- ---------- --------- -------- --------------
Loss before tax (2,158)
------------------------------------- ---------- --------- -------- --------------
Unaudited six months ended 30 June
2015 restated
--------------
Rest
of
Americas Europe World Consolidated
GBP'000 GBP'000 GBP'000 GBP'000
------------------------------------- ------------- ----------- ---------- --------------
Revenue - continuing operations 19,758 6,756 2,808 29,322
------------------------------------- ------------- ----------- ---------- --------------
Profit/(loss) from operations
- underlying 2,048 (530) (1,888) (370)
------------------------------------- ------------- ----------- ---------- --------------
Non-recurring items and amortisation
of acquired intangibles (303) 435 - 132
Profit/(loss) from operations 1,745 (95) (1,888) (238)
------------------------------------- ------------- ----------- ---------- --------------
Investment income 1
Finance costs (872)
------------------------------------- ------------- ----------- ---------- --------------
Loss before tax (1,109)
------------------------------------- ------------- ----------- ---------- --------------
4. Dividends
Unaudited Unaudited
six months six months
ended ended
30 June 30 June
2016 2015
GBP'000 GBP'000
--------------------------------------- ----------- -----------
Amounts recognised as distributions
to equity holders in the period:
--------------------------------------- ----------- -----------
Final dividend in respect of the
year ended 31 December 2015 of GBPnil
(2014: 0.595p) per share - 2,902
Interim dividend in respect of the
year ended 31 December 2015 of GBPnil - 1,116
--------------------------------------- ----------- -----------
- 4,018
--------------------------------------- ----------- -----------
Dividends are not payable on treasury shares or shares held in
the employee share trusts which have waived their entitlement to
dividends.
The amount of the dividend waived in 2016 (in respect of the
year ended 31 December 2015) was GBPnil.
The Company did not pay an interim dividend for 2015 and no
final dividend for 2015 will be paid.
5. Taxation
The effective tax rate on the reported profit before tax for the
half year is 82% (H1 2015 restated: 83%). The effective tax rate on
the reported profit before tax as adjusted for the impact of
non-recurring items and the accounting for amortisation of
acquisition intangibles charge for the half year is 75% (H1 2015
restated: 84%). Of the total tax charge, GBPnil (H1 2015: GBPnil)
arises in respect of the UK with the remainder of the charge
arising outside the UK.
6. (Loss)/earnings per share
The calculation of the (loss)/earnings per share is based on the
following data:
Unaudited Unaudited Unaudited
six months six months six months
ended ended ended
30 June 30 June 30 June 2016
2016 2016 Discontinued
Total Continuing GBP'000
GBP'000 GBP'000
-------------------------------------- ----------- ----------- -------------
Loss
Loss for the purposes of basic
and diluted loss per share being
net loss for the period attributable
to owners of the Company (20,763) (3,931) (16,832)
Amortisation of acquired intangibles 304 304 -
Non-recurring items 1,536 (654) 2,190
Tax on non-recurring items (908) (115) (793)
-------------------------------------- ----------- ----------- -------------
Loss for purpose of basic earnings
per share - underlying (19,831) (4,396) (15,435)
-------------------------------------- ----------- ----------- -------------
Unaudited Unaudited Unaudited
six months six months six months
ended ended ended
30 June 30 June 30 June
2015 2015 2015
re-presented re-presented re-presented
Total Continuing Discontinued
GBP'000 GBP'000 GBP'000
--------------------------------------- ------------- ------------- -------------
Earnings/(Loss)
Earnings/(Loss) for the purposes
of basic and diluted earnings
per share being net profit/(loss)
for the period attributable to
owners of the Company 1,407 (2,034) 3,441
Amortisation of acquired intangibles 303 303 -
Non-recurring items (435) (435) -
Tax on non-recurring items (115) (115) -
--------------------------------------- ------------- ------------- -------------
Earnings/(loss) for purpose of
basic earnings per share - underlying 1,160 (2,281) 3,441
--------------------------------------- ------------- ------------- -------------
2016 2015
Number Number
million million
------------------------------------------- -------- --------
Number of shares
Weighted average number of ordinary shares
for the purposes of basic earnings per
share 499.8 490.5
Effect of dilutive potential ordinary
shares:
- share options and performance share
plan 7.1 4.5
------------------------------------------- -------- --------
Weighted average number of ordinary shares
for the purposes of diluted earnings
per share 506.9 495.0
------------------------------------------- -------- --------
2016 2016 2016
All Continuing Discontinued
Pence Pence Pence
------------------------------------ ------ ----------- -------------
Basic loss per share (4.2) (0.8) (3.4)
Diluted loss per share (4.2) (0.8) (3.4)
Basic loss per share - underlying (4.0) (0.9) (3.1)
Diluted loss per share - underlying (4.0) (0.9) (3.1)
------------------------------------- ------ ----------- -------------
2015 2015 2015
All Continuing Discontinued
Pence Pence Pence
---------------------------------- ------ ----------- -------------
Basic earnings/(loss) per share 0.3 (0.4) 0.7
Diluted earnings/(loss) per share 0.3 (0.4) 0.7
Basic earnings/(loss) per share
- underlying 0.2 (0.5) 0.7
Diluted earnings/(loss) per share
- underlying 0.2 (0.5) 0.7
----------------------------------- ------ ----------- -------------
The average share price for the six months ended 30 June 2016
was 15.2p (30 June 2015: 15.7p).
7. Notes to the cash flow statement
Unaudited Unaudited
six months six months
ended ended
30 June 30 June
2016 2015
GBP'000 GBP'000
------------------------------------------- ----------- -----------
(Loss) from continuing operations (1,577) (238)
Profit from discontinuing operations 639 7,463
------------------------------------------- ----------- -----------
(Loss)/profit from operations (938) 7,225
------------------------------------------- ----------- -----------
Adjustments for:
Depreciation of property, plant and
equipment 400 417
Amortisation of intangible assets 896 855
Loss/(profit) on disposal of plant
and equipment 19 (7)
Adjustment for cost of share-based
payments 1,403 842
Decrease in provisions (157) (1,996)
Other non-recurring items (81) -
Other non-cash items - 158
------------------------------------------- ----------- -----------
Operating cash flows before movements
in working capital 1,542 7,494
------------------------------------------- ----------- -----------
Increase in receivables (6,593) (1,708)
Increase/(decrease) in payables 2,066 (8,650)
------------------------------------------- ----------- -----------
Cash absorbed by operations (2,985) (2,864)
Income taxes paid (2,704) (4,206)
------------------------------------------- ----------- -----------
Net cash outflow from operating activities (5,689) (7,070)
------------------------------------------- ----------- -----------
8. Discontinued operations
The French and related operations of Kurt Salmon were reported
as discontinued operations in the Group financial statements for
the year ended 31 December 2015 and the financial impact of the
finalisation of the disposal of that business is reported in the
discontinued operations caption in the interim statements for the
six month period ended 30 June 2016. The assets and liabilities of
the French and related operations of Kurt Salmon were shown in the
Group balance sheet at 31 December 2015 as assets and liabilities
held for sale, of GBP91.8m and GBP33.1m respectively and were
derecognised when the transaction completed on 7 January 2016.
The healthcare consulting practice formed part of the reported
continuing operations of Kurt Salmon in the Group financial
statements for the year ended 31 December 2015. The sale of the
Kurt Salmon healthcare business was completed on 29 July 2016, but
given that the negotiations for the sale of the business were at an
advanced stage at 30 June 2016, the results of its operations and
the loss on disposal arising from the impairment of goodwill are
reported as discontinued operations in the interim statements for
the six month period ended 30 June 2016. The comparatives for the
six month period to 30 June 2015 have been restated on the same
basis in relation to continuing and discontinued operations. The
assets and liabilities of the Kurt Salmon healthcare business are
shown in the Group balance sheet at 30 June 2016 as assets and
liabilities held for sale of GBP9.3m and GBP1.5m respectively. The
assets held for sale include the impaired goodwill related to the
healthcare business of GBP5.8m.
The Kurt Salmon retail and consumer group operations formed part
of the reported continuing operations of Kurt Salmon in the Group
financial statements for the year ended 31 December 2015. The group
entered into a sale agreement to dispose of the Kurt Salmon retail
and consumer goods business on 21 September 2016. The sale is
expected to complete in October or November 2016. The proceeds of
disposal are expected to exceed the book value of the related net
assets and accordingly no impairment losses have been recognised.
The comparatives for the six month period to 30 June 2015 have been
restated on the same basis in relation to continuing and
discontinued operations. The assets and liabilities of the Kurt
Salmon consumer group business are shown in the Group balance sheet
at 30 June 2016 as assets and liabilities held for sale of
GBP132.4m and GBP41.4m respectively.
Kurt Salmon Kurt Salmon Kurt Salmon
France Healthcare Consumer Total
unaudited unaudited Group unaudited unaudited
six months six months six months six months
ended ended 30 ended 30 ended
30 June June 2016 June 2016 30 June
2016 2016
GBP'000 GBP'000 GBP'000 GBP'000
------------------------------- ----------- ----------- ---------------- -----------
Revenue - 7,321 40,429 47,750
Cost of sales - (6,076) (27,517) (33,593)
------------------------------- ----------- ----------- ---------------- -----------
Gross profit - 1,245 12,912 14,157
------------------------------- ----------- ----------- ---------------- -----------
Administrative expenses
- underlying (60) (2,224) (9,044) (11,328)
(Loss)/profit from operations
- underlying (60) (979) 3,868 2,829
Administrative expenses
- non-recurring 75 (1,607) (658) (2,190)
------------------------------- ----------- ----------- ---------------- -----------
Total administrative expenses 15 (3,831) (9,702) (13,518)
------------------------------- ----------- ----------- ---------------- -----------
Profit/(loss) from operations 15 (2,586) 3,210 639
Investment income - - - -
Finance costs - - (109) (109)
------------------------------- ----------- ----------- ---------------- -----------
Profit/(loss) before tax 15 (2,586) 3,101 530
Tax - - (1,569) (1,569)
------------------------------- ----------- ----------- ---------------- -----------
Profit/(loss) for the
period attributable to
owners of the Company 15 (2,586) 1,532 (1,039)
Profit/(Loss) on disposal
from discontinued operations 612 (16,405) - (15,793)
------------------------------- ----------- ----------- ---------------- -----------
Net profit/(loss) attributable
to discontinued operations 627 (18,991) 1,532 (16,832)
------------------------------- ----------- ----------- ---------------- -----------
Kurt Salmon Kurt Salmon
Kurt Salmon Healthcare Consumer Total
France unaudited Group unaudited unaudited
unaudited six months six months six months
six months ended ended 30 ended
ended 30 30 June June 2015 30 June
June 2015 2015 2015
GBP'000 GBP'000 GBP'000 GBP'000
---------------------------------------- ----------- ----------- ---------------- -----------
Revenue 49,195 8,612 37,064 94,871
Cost of sales (35,132) (6,978) (23,754) (65,864)
---------------------------------------- ----------- ----------- ---------------- -------------
Gross profit 14,063 1,634 13,310 29,007
---------------------------------------- ----------- ----------- ---------------- -------------
Administrative expenses - underlying (10,347) (1,578) (9,609) (21,534)
Profit from operations - underlying 3,716 56 3,701 7,473
Administrative expenses - non-recurring - - - -
---------------------------------------- ----------- ----------- ---------------- -------------
Total administrative expenses (10,347) (1,578) (9,609) (21,534)
---------------------------------------- ----------- ----------- ---------------- -------------
Profit from operations 3,716 56 3,701 7,473
Investment income 4 - 4 8
Finance costs (671) - (107) (778)
---------------------------------------- ----------- ----------- ---------------- -------------
Profit before tax 3,049 56 3,598 6,703
Tax (965) - (2,297) (3,262)
---------------------------------------- ----------- ----------- ---------------- -------------
Profit for the period attributable to
owners of the Company 2,084 56 1,301 3,441
Result on disposal from discontinued - - -
operations -
---------------------------------------- ----------- ----------- ---------------- -------------
Net profit attributable to discontinued
operations 2,084 56 1,301 3,441
---------------------------------------- ----------- ----------- ---------------- -------------
Kurt Salmon France's non-recurring credit relates to the release
of a surplus transaction bonus. Non-recurring expenses attributed
to the Kurt Salmon Healthcare disposal comprise GBP1.0m of
non-recurring expenses related to share awards and GBP0.6m of
closure costs. There were no non-recurring items recognised by the
discontinued operations in the prior year.
The Kurt Salmon France gain on disposal reflects the taxable
gain that crystallised at completion in respect of certain elements
of the businesses sold net of GBP3.2m of currency translation
reserve credits, which are realised in the year the transaction was
completed and a post-closing adjustment of GBP1.1m, which has no
impact on cash flows. A tax charge of GBP1.8m is expected to arise
upon completion of the KS Healthcare sale and this will be reported
in the second half of 2016.
The GBP16.4m Kurt Salmon healthcare loss on disposal arises as a
result of the impairment of goodwill relating to the disposal
group. The impairment charge represents the difference between the
goodwill and net assets attributed to the disposal group and
estimated consideration after post-closing adjustments net of
transaction costs.
During the period, the Kurt Salmon healthcare disposal group
contributed a cash outflow of GBP1.5 million (2015: GBP1.2 million
outflow) to the group's net operating cash flows. The Kurt Salmon
retail and consumer goods disposal group contributed a cash inflow
of GBP4.0million (2015: GBP4.2m). There were no cash flows arising
from investing or financing in these businesses in either the
current or prior year.
The cash flows arising from the disposal of Kurt Salmon France
and related entities have been presented as proceeds from the
disposal of subsidiaries in the Group cash flow statement.
The major classes of assets and liabilities comprising the
operations classified as held for sale were as at 30 June 2016 were
follows:
Kurt Salmon
Kurt Salmon Consumer
Healthcare Group Total
Unaudited Unaudited Unaudited
six months six months six months
ended ended ended
30 June 30 June 30 June
2016 2016 2016
GBP'000 GBP'000 GBP'000
--------------------------------- ----------- ----------- -----------
Intangible assets and goodwill 5,801 94,312 100,113
Property, plant and equipment 15 1,483 1,498
Financial assets - 472 472
Deferred tax asset - 10,897 10,897
Trade and other receivables 3,448 24,300 27,748
Current tax receivable - 961 961
Assets held for sale 9,264 132,425 141,689
--------------------------------- ----------- ----------- -----------
Trade and other payables (1,535) (19,896) (21,431)
Current tax liabilities - (1,668) (1,668)
Retirement benefit obligations - (12,072) (12,072)
Non-current tax liabilities - (7,005) (7,005)
Long term provisions - (743) (743)
Liabilities held for sale (1,535) (41,384) (42,919)
--------------------------------- ----------- ----------- -----------
Net assets of the disposal group 7,729 91,041 98,770
--------------------------------- ----------- ----------- -----------
9. Financial instruments fair value disclosure
The directors consider that the carrying value amounts of
financial assets and financial liabilities recorded at amortised
cost in the condensed financial statements included in this
half-yearly report are approximately equal to their fair
values.
The directors note that, whilst the carrying value of the
Alexander Proudfoot goodwill is supportable as at 30 June 2016, the
headroom in relation to this Cash Generating Unit has reduced
significantly in recent years. As a result, sensitivity analysis on
the key assumptions included in the impairment review indicates
that a reasonably possible change in key assumptions could, in the
foreseeable future, result in the recoverable amount falling below
the carrying value.
INDEPENDENT REVIEW REPORT TO MANAGEMENT CONSULTING GROUP PLC
We have been engaged by the company to review the condensed set
of financial statements in the half-yearly financial report for the
six months ended 30 June 2016 which comprises the condensed group
statement of profit and loss, the condensed group statement of
comprehensive income, the condensed group statement of changes in
equity, the condensed group statement of financial position, the
condensed group statement of cash flows, and related notes 1 to 9.
We have read the other information contained in the half-yearly
financial report and considered whether it contains any apparent
misstatements or material inconsistencies with the information in
the condensed set of financial statements.
This report is made solely to the company in accordance with
International Standard on Review Engagements (UK and Ireland) 2410
"Review of Interim Financial Information Performed by the
Independent Auditor of the Entity" issued by the Auditing Practices
Board. Our work has been undertaken so that we might state to the
company those matters we are required to state to it in an
independent review report and for no other purpose. To the fullest
extent permitted by law, we do not accept or assume responsibility
to anyone other than the company, for our review work, for this
report, or for the conclusions we have formed.
Directors' responsibilities
The half-yearly financial report is the responsibility of, and
has been approved by, the directors. The directors are responsible
for preparing the half-yearly financial report in accordance with
the Disclosure and Transparency Rules of the United Kingdom's
Financial Conduct Authority.
As disclosed in note 2, the annual financial statements of the
group are prepared in accordance with IFRSs as adopted by the
European Union. The condensed set of financial statements included
in this half-yearly financial report has been prepared in
accordance with International Accounting Standard 34 "Interim
Financial Reporting" as adopted by the European Union.
Our responsibility
Our responsibility is to express to the Company a conclusion on
the condensed set of financial statements in the half-yearly
financial report based on our review.
Scope of review
We conducted our review in accordance with International
Standard on Review Engagements (UK and Ireland) 2410 "Review of
Interim Financial Information Performed by the Independent Auditor
of the Entity" issued by the Auditing Practices Board for use in
the United Kingdom. A review of interim financial information
consists of making inquiries, primarily of persons responsible for
financial and accounting matters, and applying analytical and other
review procedures. A review is substantially less in scope than an
audit conducted in accordance with International Standards on
Auditing (UK and Ireland) and consequently does not enable us to
obtain assurance that we would become aware of all significant
matters that might be identified in an audit. Accordingly, we do
not express an audit opinion.
Conclusion
Based on our review, nothing has come to our attention that
causes us to believe that the condensed set of financial statements
in the half-yearly financial report for the six months ended 30
June 2016 is not prepared, in all material respects, in accordance
with International Accounting Standard 34 as adopted by the
European Union and the Disclosure and Transparency Rules of the
United Kingdom's Financial Conduct Authority.
Deloitte LLP
Chartered Accountants and Statutory Auditor
London, United Kingdom
22 September 2016
This information is provided by RNS
The company news service from the London Stock Exchange
END
IR ELLBLQKFFBBB
(END) Dow Jones Newswires
September 22, 2016 02:05 ET (06:05 GMT)
Management Consulting (LSE:MMC)
Historical Stock Chart
From Apr 2024 to May 2024
Management Consulting (LSE:MMC)
Historical Stock Chart
From May 2023 to May 2024